NEW YORK, April 3 - MetriGenix and Temple University plan to develop protein chips that target cardiovascular disease, the company said today.
Under the terms of the collaboration, Temple scientists will provide MetriGenix with a selection of proteins linked to congestive heart failure culled from in-house research and general literature. MetriGenix, in turn, will use its 4D assay system to produce flow-thru biochips with antibodies to monitor these proteins.
The agreement also calls for researchers at Temple to use the 4D system to screen some 350 archived human myocardial tissue samples with an expanded molecular target set. This part of the deal got some financial help from the National Institute of Aging, according to MetriGenix.
Financial terms of the agreement were not disclosed.